Island Pharmaceuticals Expands US Biodefence Engagement Ahead of Trials
Key points
- Island appoints Mark Herzog as Senior Global Health Security Advisor
- Herzog brings over 25 years of experience in biodefence and government contracting
- Island joins MC2 working groups for R&D and procurement
- Engagements aim to support Galidesivir development under FDA Animal Rule
Full summary
Island Pharmaceuticals Ltd has expanded its US biodefence engagement ahead of the planned FDA Animal Rule studies for Galidesivir, an antiviral drug candidate for Marburg Virus Disease. The company appointed Mark Herzog as Senior Global Health Security Advisor, leveraging his 25 years of experience in biodefence, government contracting, and medical countermeasure initiatives. Herzog's role will enhance Island's strategic engagement with key US agencies, including the Department of Defense, Department of Health and Human Services, and Biomedical Advanced Research and Development Authority. Additionally, Island has secured representation on the Medical Countermeasures Coalition working groups, focusing on countermeasure R&D, procurement, and stockpiling policy. These initiatives aim to strengthen Island's positioning in the US biodefence ecosystem and support Galidesivir's development towards potential regulatory approval and procurement opportunities.
Guidance
null
Outlook
null
Summary generated by a large language model. Please interpret with care.